|
1
|
de Groen PC, Gores GJ, LaRusso NF,
Gunderson LL and Nagorney DM: Biliary tract cancers. N Engl J Med.
341:1368–1378. 1999.
|
|
2
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nakeeb A, Pitt HA, Sohn TA, et al:
Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and
distal tumors. Ann Surg. 224:463–475. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malhi H and Gores GJ: Cholangiocarcinoma:
modern advances in understanding a deadly old disease. J Hepatol.
45:856–867. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jarnagin WR and Shoup M: Surgical
management of cholangiocarcinoma. Semin Liver Dis. 24:189–199.
2004. View Article : Google Scholar
|
|
8
|
Li S, MacLachlan TK, De Luca A, Claudio
PP, Condorelli G and Giordano A: The cdc-2-related kinase, PISSLRE,
is essential for cell growth and acts in G2 phase of the cell
cycle. Cancer Res. 55:3992–3995. 1995.PubMed/NCBI
|
|
9
|
Kasten M and Giordano A: Cdk10, a
Cdc2-related kinase, associates with the Ets2 transcription factor
and modulates its transactivation activity. Oncogene. 20:1832–1838.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iorns E, Turner NC, Elliott R, et al:
Identification of CDK10 as an important determinant of resistance
to endocrine therapy for breast cancer. Cancer Cell. 13:91–104.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Leman ES, Magheli A, Yong KM, Netto G,
Hinz S and Getzenberg RH: Identification of nuclear structural
protein alterations associated with seminomas. J Cell Biochem.
108:1274–1279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kanno N, Lesage G, Phinizy JL, Glaser S,
Francis H and Alpini G: Stimulation of alpha2-adrenergic receptor
inhibits cholangiocarcinoma growth through modulation of Raf-1 and
B-Raf activities. Hepatology. 35:1329–1340. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gorunova L, Parada LA, Limon J, et al: Non
random chromosomal aberrations and cytogenetic heterogeneity in
gallbladder carcinomas. Genes Chromosomes Cancer. 26:312–321. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rijken AM, Hu J, Perlman EJ, et al:
Genomic alterations in distal bile duct carcinoma by comparative
genomic hybridization and karyotype analysis. Genes Chromosomes
Cancer. 26:185–191. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bullrich F, MacLachlan TK, Sang N, et al:
Chromosomal mapping of members of the cdc2 family of protein
kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor,
p27Kip1, to regions involved in human cancer. Cancer Res.
55:1199–1205. 1995.PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
17
|
Dong Z and Cmarik JL: Harvesting cells
under anchorage-independent cell transformation conditions for
biochemical analyses. Sci STKE. 2002:pl72002.PubMed/NCBI
|
|
18
|
Scherbakov AM, Lobanova YS, Shatskaya VA
and Krasil’nikov MA: The breast cancer cells response to chronic
hypoxia involves the opposite regulation of NF-kB and estrogen
receptor signaling. Steroids. 74:535–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sasaki K, Tsuno NH, Sunami E, et al:
Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on
colon cancer cells. BMC Cancer. 10:3702010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marin JJ, Romero MR and Briz O: Molecular
bases of liver cancer refractoriness to pharmacological treatment.
Curr Med Chem. 17:709–740. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Heller G, Ziegler B, Brandstetter A, et
al: CDK10 is not a target for aberrant DNA methylation in breast
cancer. Anticancer Res. 29:3939–3944. 2009.PubMed/NCBI
|
|
22
|
Kolch W: Coordinating ERK/MAPK signalling
through scaffolds and inhibitors. Nat Rev Mol Cell Biol. 6:827–837.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Beeram M, Patnaik A and Rowinsky EK: Raf:
a strategic target for therapeutic development against cancer. J
Clin Oncol. 23:6771–6790. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Small GW, Somasundaram S, Moore DT, Shi YY
and Orlowski RZ: Repression of mitogen-activated protein kinase
(MAPK) phosphatase-1 by anthracyclines contributes to their
antiapoptotic activation of p44/42-MAPK. J Pharmacol Exp Ther.
307:861–869. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dent P and Grant S: Pharmacologic
interruption of the mitogen-activated extracellular-regulated
kinase/mitogen-activated protein kinase signal transduction
pathway: potential role in promoting cytotoxic drug action. Clin
Cancer Res. 7:775–783. 2001.
|
|
26
|
Wen SC, Ku DH, De Luca A, Claudio PP,
Giordano A and Calabretta B: ets-2 regulates cdc2 kinase activity
in mammalian cells: coordinated expression of cdc2 and cyclin A.
Exp Cell Res. 217:8–14. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chang F, Steelman LS, Shelton JG, et al:
Regulation of cell cycle progression and apoptosis by the
Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 22:469–480.
2003.PubMed/NCBI
|
